Pharsight

Drugs that contain Octreotide Acetate

1. Mycapssa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9566246 AMRYT Pharmaceutical compositions and related methods of delivery
Sep, 2029

(5 years from now)

US8329198 AMRYT Pharmaceutical compositions and related methods of delivery
Sep, 2029

(5 years from now)

US8535695 AMRYT Pharmaceutical compositions and related methods of delivery
Sep, 2029

(5 years from now)

US9265812 AMRYT Pharmaceutical compositions and related methods of delivery
Sep, 2029

(5 years from now)

US11338011 AMRYT Method of treating diseases
Feb, 2036

(11 years from now)

US11510963 AMRYT Method of treating diseases
Feb, 2036

(11 years from now)

US10238709 AMRYT Method of treating diseases
Feb, 2036

(11 years from now)

US10695397 AMRYT Method of treating diseases
Feb, 2036

(11 years from now)

US11052126 AMRYT Method of treating diseases
Feb, 2036

(11 years from now)

US11141457 AMRYT Oral octreotide therapy and contraceptive methods
Dec, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Jun 26, 2023

Market Authorisation Date: 26 June, 2020

Treatment: Use of oral octreotide for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide; Use of oral octreotide for long-term main...

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage

MYCAPSSA family patents

Family Patents

2. Mycapssa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11857595 CHIESI Method of treating diseases
Feb, 2036

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Jun 26, 2023

Market Authorisation Date: 26 June, 2020

Treatment: Use of oral octreotide in combination with a h2-receptor antagonist or antacid for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide ...

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage

MYCAPSSA family patents

Family Patents